ALX007-ADC

ALX007-ADC is an investigational antibody-drug conjugate (ADC) targeting the fibroblast growth factor receptor-2 isoform IIIb (FGFR2b), developed by Allist Pharmaceuticals. It consists of a humanized monoclonal antibody, ALX007, conjugated to a topoisomerase I inhibitor payload via a stable and enzyme-cleavable linker. ALX007 is highly differentiated from other FGFR2b-targeting agents, such as bemarituzumab, because it recognizes a novel, non-ligand-blocking epitope. This unique binding mechanism allows the antibody to target FGFR2b-expressing cells without inhibiting the interaction between the receptor and its natural ligands, FGF7 and FGF10. By sparing this ligand-receptor interaction, ALX007-ADC is designed to minimize the risk of corneal dystrophy and other ocular toxicities commonly associated with FGFR2b blockade. Preclinical studies have demonstrated that ALX007-ADC possesses potent anti-tumor efficacy in FGFR2b-positive gastric and gastroesophageal junction (G/GEJ) cancer models while maintaining a favorable safety profile.